Journal of the American College of Clinical Pharmacy : JACCP最新文献

{"title":"Comment on “Factors associated with attaining a pharmacy residency interview: A scoping review”","authors":"Valerie Moore Pharm.D., Kirsten Ohler Pharm.D., FCCP","doi":"10.1002/jac5.1989","DOIUrl":"https://doi.org/10.1002/jac5.1989","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Navigating obstacles: Perspectives of US pharmacy residency directors on non-US candidates for PGY-1 residencies: A survey-based research”","authors":"Margaret Choye Pharm.D., Kristen H. Ohler Pharm.D., FCCP","doi":"10.1002/jac5.1993","DOIUrl":"https://doi.org/10.1002/jac5.1993","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual degree pharmacy practice faculty scholarship: Some answers but many more questions","authors":"B. Joseph Guglielmo Pharm.D.","doi":"10.1002/jac5.1984","DOIUrl":"https://doi.org/10.1002/jac5.1984","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141584060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An aspirational research model and the difficulties of implementation in the current fiscal and training landscape","authors":"Deborah S. Bondi Pharm.D., FCCP, Jennifer A. Szwak Pharm.D., FCCP, Megan A. Rech Pharm.D., M.S., FCCP","doi":"10.1002/jac5.1985","DOIUrl":"https://doi.org/10.1002/jac5.1985","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141584059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 ACCP Virtual Poster Symposium May 21 - 22, 2024","authors":"","doi":"10.1002/jac5.1986","DOIUrl":"https://doi.org/10.1002/jac5.1986","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on “Factors associated with attaining a pharmacy residency interview: A scoping review”","authors":"Suzanne Whitten Pharm.D., Beth Bryles Phillips Pharm.D., FCCP, Sharmon P. Osae Pharm.D., Rebecca H. Stone Pharm.D., FCCP, Chelsea A. Keedy Pharm.D., Blake R. Johnson Pharm.D., MPH, Amber Prentiss MLIS, Devin Lavender Pharm.D.","doi":"10.1002/jac5.1991","DOIUrl":"https://doi.org/10.1002/jac5.1991","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141583719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary considerations for nephrotoxin stewardship: Estimating kidney function and use of novel biomarkers","authors":"Sandra L. Kane-Gill Pharm.D., M.Sc., FCCP,&nbsp;Nabihah Amatullah Pharm.D.,&nbsp;Tiffany Tran Pharm.D.,&nbsp;Iman Karimzadeh Ph.D.","doi":"10.1002/jac5.2003","DOIUrl":"10.1002/jac5.2003","url":null,"abstract":"<p>Drug-associated acute kidney injury (D-AKI) constitutes approximately 19%–26% of all acute kidney injury (AKI) cases in hospitalized patients. Notably, there is often a deficiency in optimal drug management after D-AKI diagnosis, with only about half of the patients experiencing discontinuation of nephrotoxins and one-fifth avoiding further nephrotoxin administration. Nephrotoxin stewardship involves the application of coordinated care management strategies to ensure the safe utilization of nephrotoxins and renally eliminated medications. The purpose of this paper is to review nephrotoxin stewardship strategies and highlight contemporary considerations for estimating kidney function and the use of novel biomarkers as part of the stewardship program. The Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) 2021 serum creatinine formula is now recommended for estimating kidney function for adults in most clinical situations in the United States. It is time to reevaluate how healthcare professionals think of estimating kidney function for drug dosing with the use of the non-indexed, race-free, CKDEPI 2021 equation. In addition, widespread use of serum cystatin C (CysC) is anticipated so estimated glomerular filtration rate equations that incorporate serum CysC will need to be further evaluated for drug dosing recommendations and how the use of serum CysC can complement serum creatinine-based equations. Lastly, novel kidney stress/damage biomarkers should be viewed as a piece of a complex scenario of D-AKI prediction, diagnosis, and prognosis and should be interpreted along with other diagnostic criteria in relation to the clinical condition of the patient. These contemporary considerations for drug dosing and D-AKI management are important components of nephrotoxin stewardship.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists' role in combating medical misinformation","authors":"Ila M. Harris Pharm.D., FCCP,&nbsp;Michelle L. Hilaire Pharm.D., FCCP,&nbsp;Michelle Jeon Pharm.D.,&nbsp;Karen L. Kier Ph.D., FCCP,&nbsp;Faria M. Munir Pharm.D., M.S.,&nbsp;Alex S. Carmon Pharm.D.,&nbsp;Melissa V. Maffei Pharm.D.,&nbsp;S. Mimi Mukherjee Pharm.D.,&nbsp;Sharmon P. Osae Pharm.D.","doi":"10.1002/jac5.2005","DOIUrl":"10.1002/jac5.2005","url":null,"abstract":"<p>Medical misinformation can pose serious threats to public health. This commentary explores the pharmacist's unique role in addressing and mitigating the impact of medical misinformation. Pharmacists are uniquely positioned to engage with other healthcare providers, patients, and communities to dispel myths, provide accurate information, and promote evidence-based healthcare decision-making. This commentary showcases examples of the multifaceted roles of pharmacists in combating medical misinformation. It explores various strategies and interventions that can be used by pharmacists, including patient education, effective communication, information dissemination, and community engagement. Pharmacists' interventions are often at the intersection of medication management and health information needs, making them integral in ensuring patients and providers make informed healthcare choices. Moreover, this commentary highlights the impact pharmacists can have as advocates for scientific rigor and evidence-based practices within healthcare systems to educate against medical misinformation and discusses the need for continued education, training, and support for pharmacists to excel in their roles as healthcare educators and medication experts. Pharmacists have a role in countering medical misinformation when serving patients by providing information that empowers a more informed society.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141681679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring patient safety when managing concentrated insulin glargine and insulin degludec at hospital admission","authors":"Denise Kelley Pharm.D.,&nbsp;Janci Addison Pharm.D.,&nbsp;Kristin Janzen Pharm.D.,&nbsp;Steven Wulfe Pharm.D.","doi":"10.1002/jac5.1997","DOIUrl":"10.1002/jac5.1997","url":null,"abstract":"<p>The development and use of concentrated insulins have increased in recent years. This can pose unique challenges when transitioning to a non-concentrated insulin during an inpatient admission. There is no clear consensus on the recommended interchange of the various concentrated insulins in the inpatient setting, with suggestions ranging from implementing a 1:1 unit dose conversion, a minimum 20% dose reduction or selecting an approach based on the total daily dose of the concentrated insulin. In a retrospective cohort analysis at a single health system, a greater number of hypoglycemic events occurred when implementing a 1:1 unit conversion of insulin glargine 300 units/mL (iGlar300) to insulin detemir 100 units/mL (iDet100) compared to the same conversion from insulin glargine 100 units/mL (iGlar100) to iDet100. This prompted identification of a standardized approach that would improve patient safety while also being operationally feasible at a multi-hospital network. The solution of implementing a minimum 20% dose reduction successfully improved hypoglycemia rates upon transitioning from iGlar300 to iDet100, though many logistical challenges were faced. Although iDet100 is being phased off the market, adhering to this minimum 20% dose reduction is the recommended approach when transitioning from iGlar300 to iGlar100, and this challenge persists as a relevant issue. Ensuring health systems are equipped to implement dose reductions when transitioning from concentrated basal insulins to non-concentrated basal insulin counterparts is paramount for maintaining patient safety. This paper will discuss the limited evidence available supporting optimal dosing when transitioning iGlar300 and insulin degludec 200 units/mL (iDeg200) to non-concentrated basal insulins and serve as a “how to” implementation guide for other health systems, based on one health system's approach in navigating this emerging patient safety issue.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141712405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community pharmacists' experience, attitudes, and knowledge in providing care to lactating persons","authors":"Michelle M. Szabo Pharm.D.,&nbsp;Chelsea M. Baker Pharm.D., MBA,&nbsp;Mudit Gaur M.S.,&nbsp;Molly A. Nichols Pharm.D., M.S.","doi":"10.1002/jac5.1976","DOIUrl":"https://doi.org/10.1002/jac5.1976","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Breastfed infants have been shown to have a lower incidence of common childhood infections and sudden infant death syndrome. Furthermore, breastfeeding people experience lower rates of post-partum mood disorders. The majority of breastfeeding people stop breastfeeding earlier than they intend. Concern about medication use during lactation is one reason for early discontinuation. It is critical that community pharmacists are prepared to appropriately counsel lactating patients on the effects medications can have on their efforts to breastfeed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To (1) characterize community pharmacists' experience, attitudes, and knowledge regarding medication use during lactation and (2) identify factors impacting pharmacists' knowledge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 52-item electronic survey was used to collect demographics, experiences, attitudes, and knowledge regarding medication use during lactation. Community pharmacists who precepted for a Big Ten College of Pharmacy were eligible to participate in the study. Descriptive statistics were calculated using Microsoft Excel. Multivariable linear regression was performed using R (version 3.6.1) to evaluate which factors influenced total knowledge scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-eight of 1029 pharmacy preceptors (4.7%) completed the survey. The average total knowledge score for respondents was 51.3%. Most (80.0%) respondents agreed or strongly agreed they viewed themselves as valuable healthcare resources to breastfeeding patients. Most (82.5%) agreed or strongly agreed that patients who desire information about how medications can impact breastfeeding will directly ask for it. Fewer than 50% agreed or strongly agreed that pharmacy workflow supported them to look up lactation-related information while working.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pharmacists have low knowledge of medications' effects on milk supply despite their positive attitudes towards breastfeeding and belief they are valuable healthcare resources to their breastfeeding patients. Workflow barriers, expectations that patients will ask for lactation-related information if desired, and gaps in education may be key contributors to lactating patients not getting the information they need regarding medication use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}